OLD National Bancorp IN Purchases 3,020 Shares of Thermo Fisher Scientific Inc. $TMO

OLD National Bancorp IN boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 46,303 shares of the medical research company’s stock after purchasing an additional 3,020 shares during the period. OLD National Bancorp IN’s holdings in Thermo Fisher Scientific were worth $26,830,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. JPL Wealth Management LLC acquired a new stake in Thermo Fisher Scientific during the 3rd quarter valued at $28,000. Highline Wealth Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 126.9% during the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock worth $29,000 after purchasing an additional 33 shares during the last quarter. Beacon Financial Strategies CORP acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at $29,000. Olistico Wealth LLC bought a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at about $29,000. Finally, Cloud Capital Management LLC bought a new stake in Thermo Fisher Scientific during the 3rd quarter worth about $31,000. 89.23% of the stock is owned by institutional investors.

Key Headlines Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q1 results: EPS $5.44 and revenue $11.01B topped consensus (EPS and sales beats, revenue +6.2% y/y), supporting fundamentals and near-term earnings visibility. Thermo Fisher Scientific (TMO) Q1 Earnings and Revenues Top Estimates
• Positive Sentiment: Analyst support: William Blair reiterated a Buy rating citing solid core growth and potential catalysts from AI adoption and reshoring — a vote of confidence that can sustain investor interest. Thermo Fisher Scientific: Buy Rating Reiterated on Solid Core Growth and Emerging AI, Reshoring Catalysts
• Positive Sentiment: Segment performance: Growth in Laboratory Products and Biopharma Services helped offset weakness elsewhere, underpinning the beat and recurring revenue streams. Thermo Fisher posts quarterly results beat as lab products, biopharma services grow
• Neutral Sentiment: Longer-term market tailwinds: digital lab transformation (Cloud ELN) and expanding microbiology testing markets present growth opportunities but are multi-year plays. Global Cloud ELN Service Market | USA, China, India Lead | Thermo Fisher Scientific, Agilent Technologies, Dassault Systèmes Drive Digital Lab Transformation
• Neutral Sentiment: Analyst consensus: Street view remains constructive (consensus around Moderate Buy), which cushions downside but limits surprise upside absent stronger guidance. Thermo Fisher Scientific Inc. (NYSE:TMO) Given Consensus Rating of “Moderate Buy” by Analysts
• Negative Sentiment: Market reaction: shares slipped in premarket trading despite the beat, indicating profit-taking or that forward guidance/growth cadence disappointed some traders. Thermo Fisher slips in premarket despite beating Q1 forecasts
• Negative Sentiment: Product-line softness: analytical instruments and specialty diagnostics showed weakness—a risk to near-term growth if those trends persist. Thermo Fisher posts quarterly results beat as lab products, biopharma services grow

Thermo Fisher Scientific Trading Down 9.2%

Shares of NYSE TMO opened at $466.77 on Thursday. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99. The firm has a market capitalization of $173.46 billion, a P/E ratio of 26.27, a P/E/G ratio of 2.72 and a beta of 0.97. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53. The company’s 50 day simple moving average is $500.69 and its 200 day simple moving average is $550.56.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.15 EPS. On average, analysts predict that Thermo Fisher Scientific Inc. will post 24.68 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. The ex-dividend date was Friday, March 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.60%.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of research analyst reports. Wells Fargo & Company set a $683.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Stifel Nicolaus raised their price target on shares of Thermo Fisher Scientific from $583.00 to $700.00 and gave the company a “buy” rating in a report on Friday, January 9th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Wednesday, April 8th. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, TD Cowen dropped their target price on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating for the company in a research report on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $631.25.

Insider Activity

In related news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $541.20, for a total transaction of $216,480.00. Following the completion of the transaction, the executive vice president owned 20,752 shares in the company, valued at approximately $11,230,982.40. The trade was a 1.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $63,499,170. The trade was a 3.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.